Investors seem to have rediscovered the Midwest this year, pouring a record $777 million into 139 companies, according to BioEnterprise. In the first half of 2013, Midwest companies raised $351 million.
Indiana University Health fell off U.S. News’ honor roll of the nation’s top 1 percent of hospitals. Because of Obamacare and other trends, perhaps IU Health should be happy about that.
With federal research funding declining, drug companies are taking a larger role funding the medical research happening at IU and universities around the country. That’s not the same thing as paying to market drugs, but it’s hardly without controversy.
The Indiana University School of Medicine plans to hire 100 research professors over the next five years in a bid to vault into the top 25 medical schools.
If this week’s D.C. appeals court ruling stands up—declaring the Obamacare tax subsidies illegal in Indiana and most other states—Gov. Mike Pence could face significant pressure, even from traditional Republican supporters, to keep the tax credits flowing.
Indianapolis-based Lilly and Co. lost 17 percent of its revenue during the second quarter as U.S. patents expired on its bestselling drugs Cymbalta and Evista.
Dow AgroSciences LLC posted sales of $1.9 billion in the second quarter, an increase of 3 percent over last year's second period, the Indianapolis-based company reported Wednesday morning.
One of the open secrets in health care is that hospitals are paid substantially more than independently owned health care facilities for the same procedures. But those higher fees are facing unprecedented pressure.
All of sudden, Hoosiers are buying less health care. Is that because we’ve kicked the habit, sobered up and found religion? Or is it the Great Recession hangover that will pass, eventually, so we can all get back to the party?
Indianapolis ranked fifth highest among the nation’s largest cities for the most positive reviews of physicians. On a five-point Patient Happiness Index, the average review by patients scored Indianapolis physicians at a 4.05. San Francisco physicians topped the list.
Indiana physicians and research organizations reaped more than $25 million in payments from 15 pharmaceutical firms in 2012, according to the most recent data made available by the not-for-profit group ProPublica. Lilly was the biggest spender and the IU medical school was the biggest recipient.
The economics of the Obamacare’s exchanges are proving attractive to both employers and workers, but a new poll shows that workers still don’t want to end up in them.
The areas around each of Indiana’s research university campuses—Bloomington, Indianapolis, Lafayette and South Bend—all boast outsize concentration of life sciences workers. Yet the state still lags on research, development and investment funding.
A new study found that common blood tests performed by hospital-owned facilities in the Indianapolis area were six to nine times more expensive than the same tests at independent lab facilities. Ouch!
Health care and health insurance were a mess long before Obamacare—and on a path to getting messier. That makes it awfully difficult to figure out how much blame and credit to give the law as it plays out in the marketplace. Here's my approach.
Since hospitals lose money on just about every patient except those with private insurance, they have been closing inner-city facilities and opening new facilities in the suburbs for the past four decades.
My post on a presentation by Community Health Network CEO Bryan Mills was interpreted in a stronger way than I intended. So let me set the record straight.
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.
In a video presentation to his employees, Community Health CEO Bryan Mills discusses the threats hospitals face from retail clinics and employers—and how Community briefly discussed laying off 1,000 workers last year.
Medtronic Inc., the second-largest maker of medical devices, will be based in Ireland after the acquisition for tax advantages.
